| vitamin E, selegiline, vitamin E + selegiline |
patients
with moderate AD (N = 341) |
vitamin E (2000 IU/day), selegiline (10 mg/day); vitamin
E
+ selegiline administered for 2 years |
patients with
moderately severe cognitive impairment reported
a reduction in the functional progression of the disease |
(124) |
| vitamin E, memantine, vitamin E + memantine |
patients
with mild to moderate AD (N = 613) |
vitamin E (1000 IU twice daily), memantine (10 mg
twice daily
over 4 weeks) for 5 years |
in patients with mild to moderate
AD, vitamin E resulted in
slower functional decline; no significant differences were observed
in the groups receiving memantine alone or vitamin E + memantine |
(125) |
| vitamin E, vitamin C |
patients with
mild to moderate AD (N = 23) |
vitamin E (400 IU/day), duration not known; vitamin
C (1000
mg/day) for 1 year |
daily intake of vitamin C combined
vitamin E did not significantly
affect the course of AD over a year |
(126) |
| vitamin E, vitamin C, α-lipoic acid |
patients
with mild to moderate AD (N = 78) |
placebo, vitamin E (800 IU/day), vitamin C (500 mg/day),
α-lipoic
acid (900 mg/day), or CoQ10 (400 mg, 3 times/day) for 4 months |
no significant differences observed in CSF antioxidative biomarker
levels |
(127) |
| Gingko biloba |
subjects with normal cognition (N = 2587) or MCI (N = 482) |
placebo, Gingko biloba extract (120 mg, twice
daily) with a median follow-up time of 6.1 years |
Gingko biloba extract was ineffective in reducing
the incidence rate of dementia or AD (or possibly MCI) in the subjects;
is it MCI or AD as title says MCI? |
(128) |
| desferriox-amine (DFO) |
patients with probable AD (N = 48) |
no treatment,
placebo, DFO (125 mg intramuscularly twice daily,
5 days per week, for 24 months) |
DFO treatment significantly
reduced the rate of decline in
daily skills |
(129) |
| selenium, probiotics, selenium
+ probiotics |
patients with AD (N = 79) |
Se (200 mg/day) plus
probiotic containing Lactobacillus
acidophilus, Bifidobacterium bifidum, and Bifidobacterium longum (2 × 109 CFU/day each) |
selenium and probiotic
cosupplementation was reported to improve
cognitive function and metabolic profiles in AD patients |
(130) |
| curcumin |
nondemented individuals (N = 40) |
curcumin (90 mg twice daily), for
18 months; what type of trial? |
daily oral supplementation
likely lead to improved memory and
attention |
(131) |
